Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™: The Antares study

Antonio L. Bartorelli; Daniela Trabattoni; Piero Montorsi; Franco Fabbiocchi; Stefano Galli; Paolo Ravagnani; Luca Grancini; Sergio Cozzi; Alessandro Loaldi

doi:10.1002/ccd.10037

Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™: The Antares study

Antonio L. Bartorelli, Daniela Trabattoni, Piero Montorsi, Franco Fabbiocchi, Stefano Galli, Paolo Ravagnani, Luca Grancini, Sergio Cozzi, Alessandro Loaldi

Centro Cardiologico Monzino

Research output: Contribution to journal › Article › peer-review

Abstract

The effect of stent coatings in preventing early thrombotic occlusion remains to be proved. The purpose of this study was to evaluate the safety and efficacy of the Carbostent™, a new coronary stent with a nonthrombogenic coating (Carbofilm™), in 110 consecutive patients (73.6% men, mean age 61 ± 9 years) who met prespecified clinical and angiographic inclusion criteria and were treated with aspirin monotherapy after stenting. Stable angina (75.5%), unstable angina (18.2%), and silent ischemia (6.3%) were clinical indications for coronary revascularization. Patients received 10,000 U of heparin and no IIb/IIIa inhibitors or postprocedural heparin. Complex lesion characteristics (B2, C) were present in 39 out of 129 (30.2%) lesions. Mean lesion length was 15.6 ± 7.4 mm, and 32% of the lesions were >15 mm (range 16-52 mm). Small coronary vessels (

Original language	English
Pages (from-to)	150-156
Number of pages	7
Journal	Catheterization and Cardiovascular Interventions
Volume	55
Issue number	2
DOIs	https://doi.org/10.1002/ccd.10037
Publication status	Published - 2002

Keywords

Antiplatelet therapy
Coated stents
Stent thrombosis
Thromboresistance

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Radiology Nuclear Medicine and imaging

Access to Document

10.1002/ccd.10037

Fingerprint Dive into the research topics of 'Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™: The Antares study'. Together they form a unique fingerprint.

Cite this

Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™ : The Antares study. / Bartorelli, Antonio L.; Trabattoni, Daniela ; Montorsi, Piero ; Fabbiocchi, Franco ; Galli, Stefano ; Ravagnani, Paolo ; Grancini, Luca; Cozzi, Sergio; Loaldi, Alessandro.

In: Catheterization and Cardiovascular Interventions, Vol. 55, No. 2, 2002, p. 150-156.

Research output: Contribution to journal › Article › peer-review

Bartorelli, Antonio L. ; Trabattoni, Daniela ; Montorsi, Piero ; Fabbiocchi, Franco ; Galli, Stefano ; Ravagnani, Paolo ; Grancini, Luca ; Cozzi, Sergio ; Loaldi, Alessandro. / Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™ : The Antares study. In: Catheterization and Cardiovascular Interventions. 2002 ; Vol. 55, No. 2. pp. 150-156.

@article{c54004435cb7496893834ef381fb5046,

title = "Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent{\texttrademark}: The Antares study",

abstract = "The effect of stent coatings in preventing early thrombotic occlusion remains to be proved. The purpose of this study was to evaluate the safety and efficacy of the Carbostent{\texttrademark}, a new coronary stent with a nonthrombogenic coating (Carbofilm{\texttrademark}), in 110 consecutive patients (73.6% men, mean age 61 ± 9 years) who met prespecified clinical and angiographic inclusion criteria and were treated with aspirin monotherapy after stenting. Stable angina (75.5%), unstable angina (18.2%), and silent ischemia (6.3%) were clinical indications for coronary revascularization. Patients received 10,000 U of heparin and no IIb/IIIa inhibitors or postprocedural heparin. Complex lesion characteristics (B2, C) were present in 39 out of 129 (30.2%) lesions. Mean lesion length was 15.6 ± 7.4 mm, and 32% of the lesions were >15 mm (range 16-52 mm). Small coronary vessels (",

keywords = "Antiplatelet therapy, Coated stents, Stent thrombosis, Thromboresistance",

author = "Bartorelli, {Antonio L.} and Daniela Trabattoni and Piero Montorsi and Franco Fabbiocchi and Stefano Galli and Paolo Ravagnani and Luca Grancini and Sergio Cozzi and Alessandro Loaldi",

year = "2002",

doi = "10.1002/ccd.10037",

language = "English",

volume = "55",

pages = "150--156",

journal = "Catheterization and Cardiovascular Interventions",

issn = "1522-1946",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent™

T2 - The Antares study

AU - Bartorelli, Antonio L.

AU - Trabattoni, Daniela

AU - Montorsi, Piero

AU - Fabbiocchi, Franco

AU - Galli, Stefano

AU - Ravagnani, Paolo

AU - Grancini, Luca

AU - Cozzi, Sergio

AU - Loaldi, Alessandro

PY - 2002

Y1 - 2002

N2 - The effect of stent coatings in preventing early thrombotic occlusion remains to be proved. The purpose of this study was to evaluate the safety and efficacy of the Carbostent™, a new coronary stent with a nonthrombogenic coating (Carbofilm™), in 110 consecutive patients (73.6% men, mean age 61 ± 9 years) who met prespecified clinical and angiographic inclusion criteria and were treated with aspirin monotherapy after stenting. Stable angina (75.5%), unstable angina (18.2%), and silent ischemia (6.3%) were clinical indications for coronary revascularization. Patients received 10,000 U of heparin and no IIb/IIIa inhibitors or postprocedural heparin. Complex lesion characteristics (B2, C) were present in 39 out of 129 (30.2%) lesions. Mean lesion length was 15.6 ± 7.4 mm, and 32% of the lesions were >15 mm (range 16-52 mm). Small coronary vessels (

AB - The effect of stent coatings in preventing early thrombotic occlusion remains to be proved. The purpose of this study was to evaluate the safety and efficacy of the Carbostent™, a new coronary stent with a nonthrombogenic coating (Carbofilm™), in 110 consecutive patients (73.6% men, mean age 61 ± 9 years) who met prespecified clinical and angiographic inclusion criteria and were treated with aspirin monotherapy after stenting. Stable angina (75.5%), unstable angina (18.2%), and silent ischemia (6.3%) were clinical indications for coronary revascularization. Patients received 10,000 U of heparin and no IIb/IIIa inhibitors or postprocedural heparin. Complex lesion characteristics (B2, C) were present in 39 out of 129 (30.2%) lesions. Mean lesion length was 15.6 ± 7.4 mm, and 32% of the lesions were >15 mm (range 16-52 mm). Small coronary vessels (

KW - Antiplatelet therapy

KW - Coated stents

KW - Stent thrombosis

KW - Thromboresistance

UR - http://www.scopus.com/inward/record.url?scp=0036158478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036158478&partnerID=8YFLogxK

U2 - 10.1002/ccd.10037

DO - 10.1002/ccd.10037

M3 - Article

C2 - 11835638

AN - SCOPUS:0036158478

VL - 55

SP - 150

EP - 156

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 2

ER -